Story perspectives

mRNA Vaccines Boost Survival in Advanced Cancer Patients

10/24/2025

Summary

Story summary

University of Texas MD Anderson Cancer Center researchers find that mRNA COVID-19 vaccines may improve survival for patients with advanced lung or skin cancer under immunotherapy.
Vaccinated patients within 100 days of starting treatment had a median survival of 37.3 months, vs 20.6 months for unvaccinated patients.
The study analyzed records from over 1,000 patients and suggests the mRNA platform could boost the immune response against tumors, warranting further trials.

1 of 1

Story summary

University of Texas MD Anderson Cancer Center researchers find that mRNA COVID-19 vaccines may improve survival for patients with advanced lung or skin cancer under immunotherapy.
Vaccinated patients within 100 days of starting treatment had a median survival of 37.3 months, vs 20.6 months for unvaccinated patients.
The study analyzed records from over 1,000 patients and suggests the mRNA platform could boost the immune response against tumors, warranting further trials.